all report title image

Digestive Drugs Market, By Type (Branded and Generic), By Drug Class (5-aminosalicylates, GI stimulants, Laxatives, Antacids, H2 Antagonists, Antidiarrheals, Others), By Route of Administration (Oral, Intravenous, Others), By Application (Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome, Ulcerative Colitis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

  • Published In : Feb 2023
  • Code : CMI5542
  • Pages :250
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Digestive drugs are used to relieve gastrointestinal symptoms such as acid reflux, indigestion, and irritable bowel syndrome (IBS) among others. In addition, it is also used to treat other severe conditions such as Crohn's disease, ulcerative colitis, and hiatal hernia. The common digestive system diseases include symptoms such as abdominal pain, bloating, diarrhoea, constipation and heartburn. There are various gastrointestinal therapeutics that are used for treating various gastrointestinal conditions. For instance, acid reflux and indigestion are treated with antacids such as ranitidine and omeprazole. More severe conditions like ulcerative colitis and Crohn's disease are treated with medications such as budesonide, mesalazine and prednisolone. Few key market players manufacturing gastrointestinal drugs includes AbbVie, Alexion Pharmaceuticals, GlaxoSmithKline, Ironwood Pharmaceuticals and Janssen Pharmaceuticals among others.

Market Dynamics

Companies operating in digestive drugs market are launching new drugs which is contributing to growth of the digestive drugs market. For instance, in July 2022, JW Pharmaceutical, a South Korea based pharmaceutical company, launched Besticon a compound digestive medicine. It is composed of alverine citrate, simethicone and antispasmodic agent. Besticon is effective for patients suffering with irritable bowel syndrome, indigestion and other gastrointestinal issues. Similarly, in May 2021, Bristol Myers Squibb, a multinational pharmaceutical company received the U.S. Food and Drug Administration (FDA) approval for Zeposia for the treatment of severely active ulcerative colitis (UC). It is a sphingosine 1-phosphate (S1P) receptor modulator which reduces lymphocyte migration into the intestines.

Key features of the study:

  • This report provides an in-depth analysis of the global digestive drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global digestive drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
  • Key companies covered as a part of this study include GlaxoSmithKline plc, AbbVie Inc. (Allergan), Takeda Pharmaceutical Company Limited, Pfizer Inc, AstraZeneca plc, Marksans Pharma, Tillotts Pharma AG, Salix Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Merck & Co., Inc., Lexicon Pharmaceuticals, Inc., Bayer AG, Cadila Healthcare Ltd.
  • Global digestive drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global digestive drugs market

Detailed Segmentation:

  • Global Digestive Drugs Market, By Type
    • Branded
    • Generic
  • Global Digestive Drugs Market, By Drug Class
    • 5-aminosalicylates
    • GI stimulants
    • Laxatives
    • Antacids
    • H2 Antagonists
    • Antidiarrheals
    • Others
  • Global Digestive Drugs Market, By Route of Administration
    • Oral
    • Intravenous
    • Others
  • Global Digestive Drugs Market, By Application
    • Gastroesophageal Reflux Disease (GERD)
    • Irritable Bowel Syndrome
    • Ulcerative Colitis
    • Others (Chronic diarrhoea, constipation etc.)
  • Global Digestive Drugs Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Digestive Drugs Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • GlaxoSmithKline plc*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • AbbVie Inc. (Allergan)
    • Takeda Pharmaceutical Company Limited
    • Pfizer Inc
    • AstraZeneca plc
    • Marksans Pharma
    • Tillotts Pharma AG
    • Salix Pharmaceuticals
    • Otsuka Pharmaceutical Co., Ltd.
    • Merck & Co., Inc.
    • Lexicon Pharmaceuticals, Inc.
    • Bayer AG
    • Cadila Healthcare Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Detailed Segmentation:

  • Global Digestive Drugs Market, By Type
    • Branded
    • Generic
  • Global Digestive Drugs Market, By Drug Class
    • 5-aminosalicylates
    • GI stimulants
    • Laxatives
    • Antacids
    • H2 Antagonists
    • Antidiarrheals
    • Others
  • Global Digestive Drugs Market, By Route of Administration
    • Oral
    • Intravenous
    • Others
  • Global Digestive Drugs Market, By Application
    • Gastroesophageal Reflux Disease (GERD)
    • Irritable Bowel Syndrome
    • Ulcerative Colitis
    • Others (Chronic diarrhoea, constipation etc.)
  • Global Digestive Drugs Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Digestive Drugs Market, By Region:
    • North America
      • By Type
        • Branded
        • Generic
      • By Drug Class
        • 5-aminosalicylates
        • GI stimulants
        • Laxatives
        • Antacids
        • H2 Antagonists
        • Antidiarrheals
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Others
      • By Application
        • Gastroesophageal Reflux Disease (GERD)
        • Irritable Bowel Syndrome
        • Ulcerative Colitis
        • Others (Chronic diarrhoea, constipation etc.)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Type
        • Branded
        • Generic
      • By Drug Class
        • 5-aminosalicylates
        • GI stimulants
        • Laxatives
        • Antacids
        • H2 Antagonists
        • Antidiarrheals
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Others
      • By Application
        • Gastroesophageal Reflux Disease (GERD)
        • Irritable Bowel Syndrome
        • Ulcerative Colitis
        • Others (Chronic diarrhoea, constipation etc.)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Type
        • Branded
        • Generic
      • By Drug Class
        • 5-aminosalicylates
        • GI stimulants
        • Laxatives
        • Antacids
        • H2 Antagonists
        • Antidiarrheals
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Others
      • By Application
        • Gastroesophageal Reflux Disease (GERD)
        • Irritable Bowel Syndrome
        • Ulcerative Colitis
        • Others (Chronic diarrhoea, constipation etc.)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type
        • Branded
        • Generic
      • By Drug Class
        • 5-aminosalicylates
        • GI stimulants
        • Laxatives
        • Antacids
        • H2 Antagonists
        • Antidiarrheals
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Others
      • By Application
        • Gastroesophageal Reflux Disease (GERD)
        • Irritable Bowel Syndrome
        • Ulcerative Colitis
        • Others (Chronic diarrhoea, constipation etc.)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Type
        • Branded
        • Generic
      • By Drug Class
        • 5-aminosalicylates
        • GI stimulants
        • Laxatives
        • Antacids
        • H2 Antagonists
        • Antidiarrheals
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Others
      • By Application
        • Gastroesophageal Reflux Disease (GERD)
        • Irritable Bowel Syndrome
        • Ulcerative Colitis
        • Others (Chronic diarrhoea, constipation etc.)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Type
        • Branded
        • Generic
      • By Drug Class
        • 5-aminosalicylates
        • GI stimulants
        • Laxatives
        • Antacids
        • H2 Antagonists
        • Antidiarrheals
        • Others
      • By Route of Administration
        • Oral
        • Intravenous
        • Others
      • By Application
        • Gastroesophageal Reflux Disease (GERD)
        • Irritable Bowel Syndrome
        • Ulcerative Colitis
        • Others (Chronic diarrhoea, constipation etc.)
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.